Actinomycin D for reinduction of remission in dogs with resistant lymphoma

J Vet Intern Med. 1994 Sep-Oct;8(5):343-4. doi: 10.1111/j.1939-1676.1994.tb03247.x.

Abstract

Twenty-five dogs with malignant lymphoma refractory to chemotherapy were treated with actinomycin D at a median dose of 0.7 mg/m2 (range, 0.5 to 0.9 mg/m2) every 3 weeks. The dogs treated had received between 2 and 8 chemotherapeutic agents (median 7), for a median of 266 days before being treated with actinomycin D. For 23 of the 25 dogs, previous chemotherapy included doxorubicin. No dog responded to actinomycin D chemotherapy.

MeSH terms

  • Animals
  • Dactinomycin / therapeutic use*
  • Dog Diseases / drug therapy*
  • Dogs
  • Doxorubicin / therapeutic use
  • Female
  • Lymphoma / drug therapy
  • Lymphoma / veterinary*
  • Male
  • Neoplasm Staging / veterinary
  • Prognosis
  • Remission Induction

Substances

  • Dactinomycin
  • Doxorubicin